Amphetamine Psychosis—A Model for Paranoid Schizophrenia?



Amphetamine psychosis is at times strikingly similar to paranoid schizophrenia. How closely the exogenous model fits the endogenous psychosis is of vital interest. If such a model is valid, it would have great potential for explaining paranoid schizophrenia. This chapter presents a review of the strengths and weaknesses of amphetamine psychosis as a model for paranoid schizophrenia.


Biogenic Amine Paranoid Schizophrenia Paranoid Ideation Thought Disorder Formal Thought Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anggard, E., Jonsson, L.-E., Hogmark, A.-L., and Grunne, L.-M., 1973, Amphetamine metabolism in amphetamine psychosis, Clin. Pharmacol. Ther. 14(5):870–880.PubMedGoogle Scholar
  2. Angrist, B. M., Shopsin, B., and Gershon, S., 1971, Comparative psychotomimetic effects of stereoisomers of amphetamine, Nature, (London) 234:152–153.CrossRefGoogle Scholar
  3. Angrist, B., Shopsin, B., and Gershon, S., 1972, Metabolites of monamines in urine and cerebrospinal fluid, after large dose amphetamine administration, Psychopharmacologia (Berlin) 26:1–9.CrossRefGoogle Scholar
  4. Axelrod, J., 1972, Biogenic amines and their impact in psychiatry, Semin. Psychiatry 4(3): 199–210.PubMedGoogle Scholar
  5. Bell, D. S., 1965, Comparison of amphetamine psychosis and schizophrenia, Br. J. of Psychiatry 111:701–707.CrossRefGoogle Scholar
  6. Bell, D. S., 1973, The experimental reproduction of amphetamine psychosis, Arch. Gen. Psychiatry 29:35–40.PubMedGoogle Scholar
  7. Benakis, A., and Thomasset, M., 1970, Metabolism of amphetamines and their interaction with barbiturates and SKF-525A, in: Amphetamines and Related Compounds: Proceedings of the Mario Negri Institute for Pharmacologic Research, Milan, Italy (E. Costa and S. Garattini, eds.), pp. 153–164, Raven Press, New York.Google Scholar
  8. Bradley, C., 1937, The behavior of children receiving Benzedrine, Am. J. Psychiatry 94:577–585.Google Scholar
  9. Cameron, N., 1959, Paranoid conditions and paranoia, in: American Handbook of Psychiatry (S. Arieti, ed.), Vol. 1, p. 510, Basic Books, New York.Google Scholar
  10. Cameron, N., 1963, Personality Development and Psychopathology-A Dynamic Approach, p. 475, Houghton Mifflin Co., Boston.Google Scholar
  11. Cameron, N. A., 1967, Psychotic disorders. II. Paranoid reactions, in: Comprehensive Textbook of Psychiatry (Alfred M. Freedman and Harold I. Kaplan, eds.), p. 666, Williams & Wilkins Co., Baltimore.Google Scholar
  12. Chapman, A. H., 1954, Paranoid psychosis associated with amphetamine usage: A clinical note, Am. J. Psychiatry 111:43.PubMedGoogle Scholar
  13. Connell, P. H., 1958, Amphetamine Psychosis, Chapman and Hall, London.Google Scholar
  14. Costall, B., Naylor, R. J., and Wright, T., 1972, The use of amphetamine-induced stereotyped behavior as a model for the experimental evaluation of antiparkinson agents, Arzneim.-Forsch. 22(7): 1178–1183.Google Scholar
  15. Coyle, J. T., and Snyder, S. H., 1969, Catecholamine uptake by synaptosomes in homogenates of rat brain: Stereospecificity in different areas, J. Pharmacol. Exp. Ther. 170:221–231.PubMedGoogle Scholar
  16. Creese, I., and Iversen, S. D., 1975, The pharmacological and anatomical substrates of the amphetamine response in the rat, Brain Res. 83:419–436.PubMedCrossRefGoogle Scholar
  17. Deffenu, G., Bartolini, A., and Pepeu, G., 1970, Effect of amphetamine on cholinergic systems of the cerebral cortex of the cat, in: Amphetamines and Related Compounds: Proceedings of the Mario Negri Institute for Pharmacologic Research, Milan, Italy (E. Costa and S. Garattini, eds.), pp. 357–368, Raven Press, New York.Google Scholar
  18. Delay, J., Pichot, P., Lemperiere, T., and Sadown, R., 1954, Ann. Med-Psychol. 112(2):51.Google Scholar
  19. DSM-II (Diagnostic and Statistical Manual of Mental Disorders), 1968, 2nd Ed., American Psychiatric Association, Washington, D.C.Google Scholar
  20. Ellinwood, E. H., Jr., 1967, Amphetamine psychosis. 1. Description of the individuals and process, J. Nerv. Ment. Dis. 144:273–283.CrossRefGoogle Scholar
  21. Ellinwood, E. H., Jr., 1972, Amphetamine psychosis: Individuals, settings, and sequences, in: Current Concepts on Amphetamine Abuse (E. H. Ellinwood and S. Cohen, eds.), p. 144, National Institute of Mental Health, Rockville, Maryland.Google Scholar
  22. Ellinwood, E. H., Jr., Sudilovsky, A., Nelson, L. M., 1973, Evolving behavior in the clinical and experimental amphetamine (model) psychosis, Am. J. Psychiatry 130(10): 1088–1093.PubMedGoogle Scholar
  23. Ferris, R. M., Tang, F. L. M., Maxwell, R. A., 1972, A comparison of the capabilities of isomers of amphetamine, deoxypipradol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into the adrenergic nerves of the rabbit aorta, J. Pharmacol. Exp. Ther. 181:407–416.PubMedGoogle Scholar
  24. Fisher, E., Spatz, H., Saavedra, M., Reggiani, H., Miro, A. H., and Heller, B., 1972, Urinary elimation of phenylethylamine, Biol. Psychiatry 5(2): 139–147.Google Scholar
  25. Frey, H. H., 1970, p-Chloroamphetamine-similarities and dissimilarities to amphetamine, in: Amphetamines and Related Compounds: Proceedings of the Mario Negri Institute for Pharmacologic Research, Milan, Italy (E. Costa and S. Garattini, eds.), p. 343, Raven Press, New York.Google Scholar
  26. Fuxe, K., and Ungerstedt, U., 1968, Histochemical studies on the effect of (+)-amphetamine, drugs of the imipramine group and tryptamine on central catecholamine and 5-hydroxytryptamine neurons after intraventricular injection of catecholamines and 5-hydroxytryptamine, Eur. J. Pharmacol. 4:135–144.PubMedCrossRefGoogle Scholar
  27. Gillin, J. C., Kaplan, J., Stillman, R. C., and Wyatt, R. J., 1976, The psychedelic model of schizophrenia: The case of N,N-dimethyl-tryptamine (DMT), Am. J. Psychiatry 133:203–208.PubMedGoogle Scholar
  28. Goodwin, D. W., Alderson, P., and Rosenthal, R., 1971, Clinical significance of hallucinations in psychiatric disorders: A study of 116 hallucinatory patients, Arch. Gen. Psychiatry 24:76–80.PubMedGoogle Scholar
  29. Griffith, J. D., Cavanaugh, J., Held, J., and Oates, J. A., 1970, Experimental psychosis induced by the administration of d-amphetamine, in: Amphetamines and Related Compounds: Proceedings of the Mario Negri Institute for Pharmacologic Research, Milan, Italy (E. Costa and S. Garattini, eds.), pp. 897–904, Raven Press, New York.Google Scholar
  30. Griffith, J. D., Cavanaugh, J., Held, J., and Oates, J. A., 1972, Dextroamphetamine: Evaluation of psychotomimetic properties in man. Arch. Gen. Psychiatry 26:97–100.PubMedGoogle Scholar
  31. Grunne, E., and Lewander, T., 1967, Long-term effects of some dependence-producing drugs on the brain monamines, in: Molecular Basis of Some Aspects of Mental Activity (O. Wahaas, ed.), Vol. 2, pp. 75–81, New York.Google Scholar
  32. Harris, J. E., and Baldessarini, R. J., 1973, Uptake of [3H]catecholamines by homogenates of rat corpus striatum and cerebral cortex: Effects of amphetamine analogues, Neuropharmacology 12:669–679.PubMedCrossRefGoogle Scholar
  33. Heikkila, R. E., Orlansky, H., Mytilineou, C., and Cohen, G., 1975, Amphetamine: Evaluation of d-and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex, J. Pharmacol. Exp. Ther. 194:47–56.PubMedGoogle Scholar
  34. Himmelhoch, J. M., Detre, T., Kupfer, D. J., and Byck, R., 1972, Treatment of previously intractable depressions with tranylcypromine and lithium, J. Nerv. Ment. Dis. 155:216–220.PubMedCrossRefGoogle Scholar
  35. Hollister, L. E., 1968a, Human pharmacology of lysergic acid diethylamide (LSD), in: Psychopharmacology: A Review of Progress 1957–1967 (D. H. Efron, ed.), Public Health Service Publication 1836, pp. 1253–1261, U.S. Government Printing Office, Washington, D.C.Google Scholar
  36. Hollister, L. E., 1968b, Chemical Psychoses, pp. 117–126, Charles C. Thomas, Springfield, Illinois.Google Scholar
  37. Hornykiewicz, O., 1966, Dopamine 3-hydroxytryptamines and brain function, Pharmacol. Rev. 18(2):925–964.PubMedGoogle Scholar
  38. Innes, I. R., and Nickerson, M., 1970, Amphetamine, in: The Pharmacological Basis of Therapeutics (Louis S. Goodman and Alfred Gilman, eds.), 3rd Ed., p. 501, Macmillan Co., New York.Google Scholar
  39. Janowski, D. S., El-Yousef, K., Davis, J. M., Sekerke, H. J., 1973, Antagonist effects of physostigmine and methylphenidate in man, Am. J. Psychiatry 130(12): 1370–1376.Google Scholar
  40. Kalant, O. J., 1966, The Amphetamines-Toxicity and Addiction, p. 53, Charles C. Thomas, Springfield, Illinois.Google Scholar
  41. Kety, S. S., 1959, Biochemical theories of schizophrenia, Science 129:1–12.Google Scholar
  42. Knoll, J., 1973, Modulation of learning and retention by amphatamines, in: Pharmacology and the Future of Man: Proceedings of the Fifth International Congress on Pharmacology, San Francisco 1972, Vol. 4, pp. 55–68, S. Karger, Basel.Google Scholar
  43. Kramer, J. C., 1969, Introduction to amphetamine abuse, J. Psychedelic Drugs 11(2):1–16.Google Scholar
  44. Layne, O. L., Jr., and Yudofsky, S. C., 1971, Postoperative psychosis in cardiotomy patients: Role of organic and psychiatric factors, N. Engl. J. Med. 284:518–520.PubMedCrossRefGoogle Scholar
  45. Lehmann, H. E., 1967, Schizophrenia: Clinical features, in: Comprehensive Textbook of Psychiatry (Alfred M. Freedman and Harold I. Kaplan, eds.), p. 629, Williams & Wilkins Co., Baltimore. Licit and Illicit Drugs, 1972 (Edward M. Brecher & the Editors of Consumers Reports eds.), Consumers Union, Mt. Vernon, New York.Google Scholar
  46. Munkvad, I., Pakkenberg, H., and Randrup, A., 1968, Aminergic systems in basal ganglia associated with stereotyped behavior and catelepsy, Brain Behav. Evol. 1:89–100.CrossRefGoogle Scholar
  47. Nathanson, M. H., 1939, The central action of beta-amino-aminopropyl benzene (Benzedrine): Clinical observations, J. Am. Med. Assoc. 108:528–531.Google Scholar
  48. Penn, H., Racy, J., Lapham, L., Mandel, M., and Sandt, J., 1972, Catatonic behavior, viral encephalopathy, and death, Arch. Gen. Psychiatry 27:758–761.PubMedGoogle Scholar
  49. Post, R. M., 1973, Simulated behaviour states: An approach to specificity in psychobiological research, Biol. Psychiatry 7:237–254.PubMedGoogle Scholar
  50. Prange, A. J., Wilson, I. C., Lynn, C. W., Allsop, L. B., and Stikeleather, R. A., 1974, l-Tryptophan in mania: Contribution to a permissive hypothesis of affective disorders, Arch. Gen. Psychiatry 30:56–62.PubMedGoogle Scholar
  51. Prinzmetal, M., and Bloomberg, W., 1935, The use of Benzedrine for the treatment of narcolepsy, J. Am. Med. Assoc. 105:2051–2054.Google Scholar
  52. Randrup, A., and Munkvad, I., 1967, Stereotyped activities produced by amphetamine in several animal species and man, Psychopharmacologia (Berlin) 11:300–310.CrossRefGoogle Scholar
  53. Randrup, A. and Munkvad, I., 1970, Biochemical, anatomical, and psychological investigations of stereotyped behavior induced by amphetamines, in: Amphetamines and Related Compounds: Proceedings of the Mario Negri Institute for Pharmacologic Research, Milan, Italy (E. Costa and S. Garattini, eds.), pp. 695–713, Raven Press, New York.Google Scholar
  54. Rosenthal, D., 1970, Genetic Theory and Abnormal Behavior, McGraw-Hill, New York.Google Scholar
  55. Ross, S. B., and Renyi, A.-L., 1975, Inhibition of uptake of 3H-dopamine and 14C-5-hydroxytryptamine in mouse striatum slices, Acta Pharmacol. Toxicol. 36:56–66.CrossRefGoogle Scholar
  56. Saavedra, J. M., 1974, Enzymatic isotopic assay for and presence of β-phenylethylamine in brain, J. of Neurochem. 22:211.CrossRefGoogle Scholar
  57. Schildkraut, J. J., 1969, Neuropsychopharmacology and the affective disorders, N. Engl. J. Med. 281:302–306.PubMedCrossRefGoogle Scholar
  58. Schildkraut, J. J., 1972, Neuropharmacologically generated models of the affective disorders: Biochemical versus behavioral models, Psychopharmacol. Bull. 8(3):61–62.Google Scholar
  59. Schildkraut, J. J., and Kety, S. S., 1967, Biogenic amines and emotion, Science 156(3771):21–30.PubMedCrossRefGoogle Scholar
  60. Simpson, S. I., 1975, Blood pressure and heart rate responses evoked by d- and l-amphetamine in the pithed rat preparation, J. Pharmacol. Exp. Ther. 193:149–159.PubMedGoogle Scholar
  61. Slater, E., 1959, Amphetamine psychosis, Br. Med. J. 1:488.CrossRefGoogle Scholar
  62. Snyder, S. H., 1972, Catecholamines in the brain as mediators of amphetamine psychosis, Arch. Gen. Psychiatry 27:169–179.PubMedGoogle Scholar
  63. Stevens, J. R., 1973, An anatomy of schizophrenia?, Arch. Gen. Psychiatry 29:177–189.PubMedGoogle Scholar
  64. Taylor, K. M., and Snyder, S. H., 1970, Amphetamine: Differentiation by d and l isomers of behavior involving brain norepinephrine or dopamine, Science 168:1487–1489.PubMedCrossRefGoogle Scholar
  65. Thornburg, J. E., and Moore, K. E., 1973, Dopamine and norepinephrine uptake by rat brain synaptosomes: Relative inhibitory potencies of l-and d-amphetamine and amantadine, Res. Commun. Chem. Pathol. Pharmacol. 5:81–89.PubMedGoogle Scholar
  66. Tsuang, M. T., and Winokur, G., 1974, Criteria for sub-typing schizophrenia: Clinical differentiation of hebephrenia and paranoid schizophrenia, Arch. Gen. Psychiatry 31:43–47.PubMedGoogle Scholar
  67. Ungerstedt, U., 1971, Stereotaxic mapping of the monamine pathways in the rat brain, Acta Physiol. Scand. 367(Suppl.): 1–48.Google Scholar
  68. Van Rossum, J. M., 1970, Mode of action of psychomotor stimulant drugs, Int. Rev. Neurobiol. 12:307–383.PubMedCrossRefGoogle Scholar
  69. Wallis, G. G., McHarg, J. F., and Scott, O. C. A., 1949, Acute psychosis caused by dextroamphetamine, Br. Med. J., 2:1394.PubMedCrossRefGoogle Scholar
  70. Waud, S. P., 1938, The effects of toxic doses of benzyl methyl carbinamine (Benzedrine) in man, J. Am. Med. Assoc. 110:206.Google Scholar
  71. Welch, B. L., and Welch, A. S., 1970, Control of brain catecholamines and serotonin during acute stress and after d-amphetamine by natural inhibition of monamine-oxidase: An hypothesis, in: Amphetamines and Related Compounds: Proceedings of the Mario Negri Institute for Pharmacologic Research, Milan, Italy (E. Costa and S. Garattini, eds.), pp. 415–445, Raven Press, New York.Google Scholar
  72. Wilson, I. C., Prange, A. J., Jr., and Laura, P. P., Methyltestosterone with imipramine in men: Conversion of depression to paranoid reaction, Am. J. Psychiatry 131(1): 21–24.Google Scholar
  73. Wyatt, R. J., Murphy, D. L., Belmaker, R., Cohen, S., Donnelly, C. H., and Pollin, W., 1973, Reduced monamine oxidase activity in platelets: A possible genetic marker for vulnerability to schizophrenia, Science 179:916–918.PubMedCrossRefGoogle Scholar
  74. Wyatt, R. J., Potkin, S. G., Gillin, J. C., and Murphy, D. L., 1977a, Enzymes involved in phenylethyalmine and catecholamine metabolism in schizophrenics and controls in: Psychopharmacology: A Review of Progress 1967–1976 (M. Lipton and A. DiMascio, eds.), Raven Press, New York (in press).Google Scholar
  75. Wyatt, R. J., Gillin, J. C., Stoff, D. M., Moja, E. A., and Tinklenberg, J. R. 1977b, β- Phenylethylamine (PEA) and the neuropsychiatric disturbances, in: Neuroregulators and Psychiatric Disorders (E. Usdin, J. Barchas, and D. Hamburg, eds.), pp. 31–45, Oxford University Press. New York.Google Scholar
  76. Young, D., and Scoville, W. B., 1938, Paranoid psychosis in narcolepsy and the possible danger of Benzedrine treatment, Med. Clin. North Am. 22:637–646.Google Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  1. 1.Laboratory of Clinical Psychopharmacology, Division of Special Mental Health ResearchIRP, National Institute of Mental Health, Saint Elizabeths HospitalWashingtonUSA

Personalised recommendations